{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59"}]}],"title":"Participants with any TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"20"}]}],"title":"Participants with any serious TEAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"48"}]}],"title":"Participants with any Grade ≥ 3 TEAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"48"}]}],"title":"Participants with any product-related TEAE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"}],"units":"Participants"}],"description":"A TEAE was defined as an adverse event that started any time from initiation of product administration through and including 90 days following product administration. AEs that occurred after the initiation of subsequent anticancer therapy or product retreatment were not considered as product TEAE. AEs are graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (Version 4.03) (NCI CTCAE) guidelines where Grade 3= Severe, Grade 4= Life-threatening, and 5 = Death.","groups":[{"description":"Participants underwent leukapheresis and may receive salvage low- dose chemotherapy or one cycle of non-curative standard of care antitumor therapy if required. Eligible participants then received lymphodepleting chemotherapy with fludarabine and cyclophosphamide (flu/cy) followed by a single dose of JCAR017 (100×10\\^6 CAR+ T cells) administered intravenously (IV) 2 to 7 days after completion of lymphodepleting chemotherapy.","id":"OG000","title":"Lisocabtagene Maraleucel (JCAR017)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants who received at least one JCAR017 infusion","reportingStatus":"POSTED","timeFrame":"From first dose to 90 days following first dose (up to approximately 90 days)","title":"Number of Participants With Any Treatment-Emergent Adverse Events (TEAEs)","type":"SECONDARY","unitOfMeasure":"Participants"}